Single-cohort next-generation sequencing analysis of 713 anaplastic thyroid carcinomas: unreported gene alterations and actionable targets.

Xiaoming Zhang¹, Naiwei Chen², Sarah Claxton¹, Mikhail Kovalenko¹, Dean C Pavlick³, Matthew C Hiemenz³, Laura M Dooley⁴, Richard D Hammer¹

¹Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO, United States.

²Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, MO, United States.

³Foundation Medicine, Boston, MA, United States.

⁴Department of Otolaryngology-Head and Neck Surgery, University of Missouri School of Medicine, Columbia, MO, United States.

PubMed DOI

Abstract

OBJECTIVES: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and lethal thyroid malignancies, with limited effective treatment options. We aimed to identify previously unreported gene alterations and evaluate the potential for clinically actionable targeted therapies in ATC using the largest single next-generation sequencing (NGS) cohort to date. METHODS: This retrospective genomi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.